New hope for Tough-to-Treat colon cancer patients
NCT ID NCT07435584
Summary
This study is testing whether the drug everolimus can help control advanced colorectal cancer that has a specific genetic change called CDK12 deficiency and has stopped responding to standard treatments. The trial will first find the safest dose, then see if the drug shrinks tumors in about 38 patients. Participants will take daily pills and have regular scans to check if the cancer is responding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.